(462) Enteric-coated spherical granules for dual delivery of orlistat & acarbose with diverging properties

Current immediate-release orlistat and acarbose monotherapies have limitations, including moderate efficacy and side effects (oily stool, flatulence). Reformulating them into a single multiple-unit capsule with controlled release, synchronized with target enzyme activity, may enhance efficacy and reduce side effects (1). The target product includes three granules, one being enteric-coated and containing both drugs, despite their differing properties. This study details the preparation of this granule and the technical challenges overcome in combining the drugs.